Anti-obesity drug takes off a stone in 20 weeks

New treatment performs better than rivals and without the side effects

People taking the highest dose of a new anti-obesity drug lost more than a stone in weight in 20 weeks, a study has shown.

The amount of weight lost was almost three times that in a control group given a placebo and 50 per cent more than those given a rival treatment, which is the current brand leader for the treatment of obesity.

The drug, liraglutide, is the first of a new class of anti-obesity agents which mimic the action of a hormone that occurs naturally in the gut, reducing hunger. Experts said it had "great potential" because it also reduced the risk factors for Type 2 diabetes and heart disease. Diabetes already affects more than two million people in Britain and is rising so fast it threatens to overwhelm the NHS.

But they warned that the high cost of the drug – around £500 for six months' supply at the lowest dose – could limit its use.

Liraglutide, made by Novo Nordisk, was licensed earlier this year as a treatment for diabetes and trials have so far shown it is safe. In the first study in obese people without diabetes, published today in the Lancet, it has been shown to significantly reduce weight, with few side effects.

The study was conducted among 564 adults with a body mass index of over 30 and treated at 19 hospitals across Europe. They were put on a diet containing 500 calories fewer than they needed each day, combined with an exercise programme and given liraglutide (in one of four different doses), or orlistat (brand name Xenical, the most popular anti-obesity treatment) or a placebo.

Those on the highest 3mg dose of liraglutide lost 7.2kg on average (almost 1 stone 2lb) over 20 weeks, compared with 2.8kg on the placebo and 4.1kg with orlistat. Liraglutide cut blood pressure and improved blood glucose control, reducing the risk of diabetes.

Professor Arne Astrup, head of the department of Human Nutrition at the University of Copenhagen, Denmark, who led the study, said: "The reason why we think this drug is so intriguing is that it mimics a gut hormone called GLP-1 which is released in the small intestine after eating. It tells the body to produce more insulin and the brain to stop eating. It is a naturally occurring satiety hormone. The problem is that it is eliminated from the blood stream within minutes. The company [Novo Nordisk] has added a molecule to make it more resistant to elimination, so it lasts for a full day."

Side effects were limited to nausea and vomiting in some patients, which was easily controlled by reducing the dose of the drug, Professor Astrup said. It has to be given by injection under the skin, because the drug would be broken down in the gut, but patients found this simple using a pen-like injector similar to those used by diabetics.

Professor Astrup is a paid consultant for Novo Nordisk, but an acknowledged leader in obesity research and his paper was submitted to peer review. He said: "This class of compounds [GLP-1 analogues] have a great future if our knowledge today holds. They are very safe and they not only reduce weight but reverse risk factors associated with diabetes. The fact that they [are administered by] an injection means that a commitment from patient and doctor is needed and they are less likely to be used for purely cosmetic reasons."

Dr Colin Waine, the former chairman of the UK National Obesity Forum, said that the safety of the drug had been confirmed in trials in diabetics.

"This is the first trial I know of in non-diabetic patients. The weight loss is very significant. This class of drugs has great potential in both diabetics and non-diabetics. Professor Astrup is a world authority on obesity – this is a very promising development. But it is quite an expensive drug and that could limit its availability. We will have to see how the National Institute for Clinical Excellence rates it for cost effectiveness."

In an accompanying comment in the Lancet, George Bray, an obesity specialist at Louisiana University, US, said he was "optimistic" that the promise of the new class of drugs "will be fulfilled".

Weight pills: Drugs that help shed the pounds

Orlistat (Xenical) Also available over the counter as Alli Weight Loss Pills

It works by blocking the action of an enzyme that digests fat in the intestine and stops about a quarter of the fat eaten from being absorbed. Your body does not use the calories contained in this fat, so you start to lose weight. However, this unabsorbed fat has to go somewhere and users are prone to diarrhoea.

Sibutramine (Reductil)

Developed as an anti-depressant, it was found to aid weight loss. It boosts the levels of the neurochemicals serotonin and noradrenaline in the brain, reducing appetite. Side effects include a rise in blood pressure.

Liraglutide (Victorza)

Developed as a treatment for diabetes, it was shown to lead to weight loss. It mimics a naturally occurring gut hormone which acts on the brain, reducing hunger, and delays the emptying of the stomach, so feeling full lasts for longer. It also reduces blood pressure and helps prevent poor glucose control – cutting the risk of cardiovascular disease and diabetes.

Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Photographer / Floorplanner / Domestic Energy Assessor

    £16000 - £25000 per annum: Recruitment Genius: A Photographer/ Floor planner /...

    Ashdown Group: Front-End Developer - Surrey - £40,000

    £30000 - £40000 per annum: Ashdown Group: Front-End Developer - Guildford/Craw...

    Recruitment Genius: Customer Service Assistant

    £13500 - £15000 per annum: Recruitment Genius: A Customer Service Assistant is...

    Recruitment Genius: Sales Executive - OTE £35,000

    £16000 - £35000 per annum: Recruitment Genius: An ambitious and motivated Sale...

    Day In a Page

    Not even the 'putrid throat' could stop the Ross Poldark swoon-fest'

    Not even the 'putrid throat' could stop the Ross Poldark swoon-fest'

    How a costume drama became a Sunday night staple
    Miliband promises no stamp duty for first-time buyers as he pushes Tories on housing

    Miliband promises no stamp duty for first-time buyers

    Labour leader pushes Tories on housing
    Aviation history is littered with grand failures - from the the Bristol Brabazon to Concorde - but what went wrong with the SuperJumbo?

    Aviation history is littered with grand failures

    But what went wrong with the SuperJumbo?
    Fear of Putin, Islamists and immigration is giving rise to a new generation of Soviet-style 'iron curtains' right across Europe

    Fortress Europe?

    Fear of Putin, Islamists and immigration is giving rise to a new generation of 'iron curtains'
    Never mind what you're wearing, it's what you're reclining on

    Never mind what you're wearing

    It's what you're reclining on that matters
    General Election 2015: Chuka Umunna on the benefits of immigration, humility – and his leader Ed Miliband

    Chuka Umunna: A virus of racism runs through Ukip

    The shadow business secretary on the benefits of immigration, humility – and his leader Ed Miliband
    Yemen crisis: This exotic war will soon become Europe's problem

    Yemen's exotic war will soon affect Europe

    Terrorism and boatloads of desperate migrants will be the outcome of the Saudi air campaign, says Patrick Cockburn
    Marginal Streets project aims to document voters in the run-up to the General Election

    Marginal Streets project documents voters

    Independent photographers Joseph Fox and Orlando Gili are uploading two portraits of constituents to their website for each day of the campaign
    Game of Thrones: Visit the real-life kingdom of Westeros to see where violent history ends and telly tourism begins

    The real-life kingdom of Westeros

    Is there something a little uncomfortable about Game of Thrones shooting in Northern Ireland?
    How to survive a social-media mauling, by the tough women of Twitter

    How to survive a Twitter mauling

    Mary Beard, Caroline Criado-Perez, Louise Mensch, Bunny La Roche and Courtney Barrasford reveal how to trounce the trolls
    Gallipoli centenary: At dawn, the young remember the young who perished in one of the First World War's bloodiest battles

    At dawn, the young remember the young

    A century ago, soldiers of the Empire – many no more than boys – spilt on to Gallipoli’s beaches. On this 100th Anzac Day, there are personal, poetic tributes to their sacrifice
    Dissent is slowly building against the billions spent on presidential campaigns – even among politicians themselves

    Follow the money as never before

    Dissent is slowly building against the billions spent on presidential campaigns – even among politicians themselves, reports Rupert Cornwell
    Samuel West interview: The actor and director on austerity, unionisation, and not mentioning his famous parents

    Samuel West interview

    The actor and director on austerity, unionisation, and not mentioning his famous parents
    General Election 2015: Imagine if the leading political parties were fashion labels

    Imagine if the leading political parties were fashion labels

    Fashion editor, Alexander Fury, on what the leaders' appearances tell us about them
    Phumzile Mlambo-Ngcuka: Home can be the unsafest place for women

    Phumzile Mlambo-Ngcuka: Home can be the unsafest place for women

    The architect of the HeForShe movement and head of UN Women on the world's failure to combat domestic violence